US prevalence
~127M US adults at risk
Source: AHA 2024
ConditionICD-10: I25
Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death in the United States, accounting for ~700,000 deaths annually. It includes coronary artery disease (the most common form), heart failure, stroke, peripheral artery disease, and atrial fibrillation. Obesity and type 2 diabetes both dramatically increase CVD risk — and certain GLP-1 medications have demonstrated independent cardiovascular benefit beyond their weight-loss and glucose-lowering effects, leading to specific FDA-approved cardiovascular indications.
Quick answer
UpdatedCardiovascular disease (CVD) is the leading cause of US death — ~700,000 annually, ~50% of US adults have at least one major CVD risk factor (hypertension, obesity, diabetes, dyslipidemia). Several GLP-1s have FDA approvals for cardiovascular event reduction: Wegovy (SELECT trial 20% MACE reduction in obese non-diabetic CVD patients), Ozempic (SUSTAIN-6 26% MACE reduction), Trulicity (REWIND 12%), Victoza/Liraglutide (LEADER 13%).
- US prevalence: ~127 million adults with at least one CVD risk factor
- AHA Heart Disease & Stroke Statistics 2024
- Annual US deaths: ~700,000
- CDC leading-cause-of-death data
- Wegovy CV benefit: 20% MACE reduction (SELECT)
- Adults with obesity/overweight + established CVD
- Ozempic CV benefit: 26% MACE reduction (SUSTAIN-6)
- Adults with T2D + established CVD
- Standard CVD therapy: Statins + antihypertensives + lifestyle
- GLP-1s are adjuncts for eligible patients
Last clinical review
By GLP1Zoom editorial board
GLP-1 role
Wegovy now Medicare-covered under CVD indication (2024 expansion). Ozempic + Trulicity + Victoza FDA-approved for CV event reduction in T2D patients with established CVD.
Key takeaways
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • Tirzepatide CV outcomes trial (SURPASS-CVOT) was due to read out in 2025.
- • Coverage for the CV indication has expanded payer formularies for Wegovy in 2024-2025.
Key facts
- •CVD causes ~700,000 US deaths per year — leading cause of death
- •Wegovy FDA-approved (March 2024) to reduce risk of major cardiovascular events in adults with overweight/obesity + established CVD
- •Ozempic + Trulicity FDA-approved for cardiovascular risk reduction in type 2 diabetes
- •SELECT trial showed Wegovy reduced MACE (major adverse cardiovascular events) by 20% over ~3 years
- •Cardiovascular benefit appears independent of weight loss — direct vascular effects + inflammation reduction
- •Most US adults underestimate their personal CVD risk
Why GLP-1 medications
GLP-1 medications produce cardiovascular benefit through multiple overlapping mechanisms: weight loss reduces afterload and improves metabolic profile; glucose control reduces vascular damage in diabetic patients; direct vascular effects include reduced inflammation, improved endothelial function, and modest blood-pressure reduction. The SELECT trial (2023 NEJM) demonstrated Wegovy reduced major adverse cardiovascular events by 20% over 33 months in patients with overweight/obesity + established CVD — leading to FDA approval of a specific cardiovascular indication for Wegovy in March 2024. Similar trials drove earlier FDA cardiovascular indications for Ozempic, Trulicity, and Victoza in type 2 diabetes populations.
GLP-1 drugs prescribed for Cardiovascular Disease
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
- Wegovy$1349–$1500/mo
semaglutide
95/100 matchFDA-approved (March 2024) for cardiovascular risk reduction in adults with overweight/obesity + established CVD
Compare providers - Ozempic$968–$1100/mo
semaglutide
92/100 matchFDA-approved for cardiovascular risk reduction in type 2 diabetes (SUSTAIN-6)
Compare providers - Trulicity$987/mo
dulaglutide
88/100 matchFDA-approved for cardiovascular risk reduction in type 2 diabetes (REWIND)
Compare providers
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Wegovy semaglutide | $1349–$1500/mo | 95/100 | FDA-approved (March 2024) for cardiovascular risk reduction in adults with overweight/obesity + established CVD | Compare |
| Ozempic semaglutide | $968–$1100/mo | 92/100 | FDA-approved for cardiovascular risk reduction in type 2 diabetes (SUSTAIN-6) | Compare |
| Trulicity dulaglutide | $987/mo | 88/100 | FDA-approved for cardiovascular risk reduction in type 2 diabetes (REWIND) | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.
Common symptoms
- Chest pain, pressure, or discomfort (especially with exertion)
- Shortness of breath at rest or with mild activity
- Palpitations or irregular heartbeat sensations
- Swelling in legs, ankles, or feet (heart failure sign)
- Sudden weakness or numbness on one side (stroke warning)
- Sudden severe headache (stroke warning)
- Pain in the calf when walking (peripheral artery disease)
- Fatigue or reduced exercise tolerance
How cardiovascular disease is diagnosed
CVD diagnosis depends on the specific condition. Coronary artery disease typically diagnosed via combination of risk factor assessment (age, sex, blood pressure, lipids, diabetes status, smoking), exercise stress testing, coronary CT angiography, or invasive coronary catheterization. Heart failure diagnosis uses echocardiography, BNP/NT-proBNP labs, and clinical assessment. The American College of Cardiology/American Heart Association (ACC/AHA) risk calculator estimates 10-year CVD risk and guides preventive medication decisions including statins, ACE inhibitors, and now (for eligible patients) GLP-1 therapy.
Treatment options
Lifestyle (foundation)
Mediterranean or DASH diet, 150+ min/week moderate exercise, smoking cessation, weight management. Underpins all other treatment.
GLP-1 medications (newer cardiovascular indication)
Wegovy FDA-approved for CV risk reduction in adults with overweight/obesity + established CVD. Ozempic, Trulicity, Victoza approved for CV risk reduction in type 2 diabetes.
Statins (cholesterol)
Atorvastatin, rosuvastatin, others. Reduce LDL cholesterol and lower CV events by 25-35% in eligible patients.
Antihypertensives
ACE inhibitors, ARBs, calcium channel blockers, beta blockers. Target BP <130/80 in most adults with CVD.
Antiplatelets
Aspirin (low-dose), clopidogrel — prevent clot formation in established CVD.
SGLT2 inhibitors (newer class)
Empagliflozin, dapagliflozin — provide CV + kidney benefit in diabetic patients. Often combined with GLP-1.
Interventional / surgical
Coronary angioplasty + stent, coronary artery bypass grafting, valve replacement, implantable defibrillators per specific condition.
Compare telehealth providers for Cardiovascular Disease
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Ro· from $145/moHighest score in our rubricTelehealth · Cardiovascular Disease care
- Hers· from $99/moFDA-approved brand medicationTelehealth · Cardiovascular Disease care
- Hims· from $99/moNo video visit requiredTelehealth · Cardiovascular Disease care
- LifeMD· from $89/moBills your insuranceTelehealth · Cardiovascular Disease care
Lifestyle & self-care
- Mediterranean or DASH eating pattern — strongest evidence for CV outcomes
- 150-300 min/week moderate-intensity exercise + 2 sessions strength training
- Tobacco cessation — quitting smoking is the single highest-impact CV intervention
- Limit alcohol (≤1 drink/day women, ≤2 men per US guidelines)
- Manage stress — chronic stress contributes to hypertension and CV events
- 7-9 hours sleep per night — sleep deprivation increases CV risk
- BP self-monitoring at home if hypertensive
When to see a doctor
Make an appointment if you have:
- →Chest pain or pressure — especially if exertional, radiating, or new
- →Shortness of breath at rest or with mild activity
- →Sudden severe headache, weakness, vision change, or speech change (call 911)
- →Palpitations with lightheadedness
- →Family history of early heart disease + age ≥40 (screening recommended)
- →Diabetes, hypertension, or high cholesterol diagnosis (need comprehensive CV risk assessment)
- →Considering GLP-1 therapy with history of CVD or multiple CV risk factors
Medications for Cardiovascular Disease
Trulicity
dulaglutide
GLP1Zoom score: 5.0/10
Wegovy
semaglutide
GLP1Zoom score: 8.9/10
From $1349/mo
Ozempic
semaglutide
GLP1Zoom score: 5.8/10
From $968/mo
Zepbound
tirzepatide
GLP1Zoom score: 9.3/10
From $349/mo
Mounjaro
tirzepatide
GLP1Zoom score: 6.6/10
From $1023/mo
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizCardiovascular Disease& GLP-1 — frequently asked questions
Can GLP-1 medications treat Cardiovascular Disease?
GLP-1 medications produce cardiovascular benefit through multiple overlapping mechanisms: weight loss reduces afterload and improves metabolic profile; glucose control reduces vascular damage in diabetic patients; direct vascular effects include reduced inflammation, improved endothelial function, and modest blood-p…
Which GLP-1 medications are used for Cardiovascular Disease?
GLP-1 options associated with Cardiovascular Disease include Wegovy, Ozempic, Mounjaro, Zepbound, Trulicity. FDA approval is indication-specific — confirm the right medication with your prescriber.
Is GLP-1 therapy FDA-approved for Cardiovascular Disease?
FDA approval is indication-specific. Some GLP-1 medications are FDA-approved for Cardiovascular Disease or a closely related indication, while others are prescribed off-label under clinical judgment. Always verify the approved indication for your specific medication.
Sources
- CDC Heart Disease Facts
- SELECT Trial (NEJM 2023) — Wegovy CV outcomes
- FDA Approval Wegovy CV Indication (March 2024)
- ACC/AHA Prevention Guidelines
- ACC/AHA ASCVD Risk Estimator Plus
Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.
Diagnostic algorithm
How Cardiovascular risk is diagnosed
Who diagnoses: Primary care provider, cardiologist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
- 1
Risk factor inventory
BP, lipid panel, smoking, family history, diabetes status, BMI
Threshold: ASCVD risk calculator: 10-year CV risk estimate
- 2
ASCVD Risk Score calculation
Pooled Cohort Equations (American College of Cardiology)
Threshold: ≥7.5% 10-year risk = intermediate; ≥20% = high
- 3
Optional advanced testing
CAC score (coronary artery calcium), CT angiography, lipoprotein(a), hs-CRP
Threshold: CAC ≥100 Agatston units = high risk; ≥400 = very high
- 4
Statin initiation decision
Per 2018 ACC/AHA guidelines: age 40-75 + risk ≥7.5% + diabetes OR LDL ≥190
Threshold: Statin therapy is first-line for most elevated-risk patients
- 5
GLP-1 evaluation
For patients with established CVD + obesity (Wegovy SELECT indication) OR T2D + established CVD (Ozempic SUSTAIN-6)
Source: 2018 ACC/AHA Cholesterol Guidelines + 2019 Primary Prevention Guidelines
Treatment decision criteria
When does a GLP-1 fit Cardiovascular Disease?
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Consider GLP-1 if…
- Established CVD + obesity/overweight (Wegovy SELECT indication, Medicare-covered)
- T2D + established CVD (semaglutide/dulaglutide/liraglutide all FDA-approved for this)
- High CV risk + insufficient response to statin + lifestyle alone
Try alternatives first if…
- Primary prevention without established CVD or obesity (statins first)
- Patient achieving CV risk reduction with standard therapy (statin + BP control + lifestyle)
- Contraindication to GLP-1 (MTC history, MEN 2)
- Active pancreatitis or gastroparesis
First-line alternatives for Cardiovascular Disease
- Statin therapy
- First-line for CV risk reduction in primary + secondary prevention
- Antihypertensives
- BP control to target reduces CV events
- SGLT2 inhibitors
- For T2D + heart failure or CKD
- Lifestyle intervention
- Foundation: diet, exercise, smoking cessation
Authoritative sources on Cardiovascular Disease
- Coronary heart disease — NIH — NHLBI
- Heart disease facts — CDC